ストックスクリーナーアプリを入手
3.30
6.77%
-0.2395
前日終値:
$3.5395
開ける：
$3.41
24時間の取引高:
194.76K
Relative Volume:
0.54
時価総額：
$4.41M
収益：
-
当期純損益:
$-13.52M
株価収益率:
-4.4595
EPS:
-0.74
ネットキャッシュフロー:
$-10.03M
1週間 パフォーマンス:
-9.60%
1か月 パフォーマンス:
-34.00%
6か月 パフォーマンス:
-87.47%
1年 パフォーマンス:
-80.83%
1日の値動き範囲:
$2.86
$4.16
1週間の範囲:
$2.86
$4.16
52週間の値動き範囲:
$2.86
$79.00
Kazia Therapeutics Limited Adr Stock (KZIA) Company Profile
名前
Kazia Therapeutics Limited Adr
セクター
電話
01161298780088
住所
140 WICKS RD, NEW SOUTH WALES 2113, NSW
KZIA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KZIA
Kazia Therapeutics Limited Adr
|
3.30 | 4.41M | 0 | -13.52M | -10.03M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Kazia Therapeutics Limited Adr Stock (KZIA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-06 | 開始されました | Maxim Group | Buy |
| 2021-10-14 | 開始されました | Maxim Group | Buy |
| 2021-01-05 | 開始されました | H.C. Wainwright | Buy |
Kazia Therapeutics Limited Adr (KZIA) 最新ニュース
KAZIA THERAPEUTICS ANNOUNCES PRESENTATIONS AT UPCOMING SCIENTIFIC MEETINGS - marketscreener.com
Kazia announces voluntary delisting from ASX - marketscreener.com
KAZIA ANNOUNCES PUBLICATION IN MOLECULAR CANCER THERAPEUTICS HIGHLIGHTING PAXALISIB PRECLINICAL DATA IN MELANOMA - marketscreener.com
GBM AGILE OPENS TO PAXALISIB IN EUROPE - MarketScreener
KAZIA THERAPEUTICS ANNOUNCES CLINICAL DATA AT ESMO 2023 FROM ONGOING PHASE 1 EVT801 STUDY - marketscreener.com
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING - marketscreener.com
Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and Immunotherapy in Immunotherapy-Resistant Triple Negative Breast Cancer Model at the San Antonio Breast Cancer Symposium - marketscreener.com
KAZIA THERAPEUTICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES HOSTED BY HC WAINWRIGHT AND LD MICRO - marketscreener.com
SEC Form 424B3 filed by Kazia Therapeutics Limited - Quantisnow
Kazia Therapeutics sells Cantrixil rights for $1 million - Investing.com India
Kazia's Million-Dollar Deal: Cantrixil Cancer Drug IP Rights Sold as Development Path Shifts - Stock Titan
Kazia Therapeutics shares annual report details By Investing.com - Investing.com South Africa
Kazia Therapeutics shares annual report details - Investing.com
Best upcoming stock splits and reverse splits 2024 - Investorsobserver
Kazia Therapeutics and the Hebrew University of Jerusalem Receives a Grant from The Michael J. Fox Foundation to Evaluate the Therapeutic Potential of Paxalisib as a Treatment for Parkinson's Disease - BioSpace
Kazia explores paxalisib for Parkinson's with MJFF grant - Investing.com
KZIA’s Stock Journey: What Investors Need to Know About Kazia Therapeutics Limited ADR’s Performance - The InvestChronicle
Kazia Therapeutics Limited ADR (KZIA) Stock: Analyzing the Market Value - The News Heater
SolarBank Corporation (SUUN) Stock: Evaluating the Market Performance - The News Heater
Aditxt Inc (ADTX) Stock: A Look at the Analyst Recommendations - The News Heater
Maxim Group Begins Coverage on Kazia Therapeutics (NASDAQ:KZIA) - Defense World
10 Best ASX Stocks to Buy According to Hedge Funds - Insider Monkey
Game-Changing Cancer Trial: Kazia's New Drug Combo Could Unmask Hidden Breast Cancer Cells - StockTitan
Why Kazia Therapeutics (KZIA) Is Among the Best Australian Stocks to Buy Now? - Insider Monkey
10 Best Australian Stocks to Buy Now - Insider Monkey
Kazia Therapeutics Secures $2M Funding Through Direct Offering to Alumni Capital - StockTitan
Kazia Therapeutics secures $2 million in direct offering - Investing.com India
Kazia Therapeutics Secures $2M Funding Through Direct Offering at $1.50 Per ADS - StockTitan
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday? - Yahoo Finance
Kazia aligns with FDA on glioblastoma drug study design - Investing.com India
Kazia's Brain Cancer Drug Paxalisib Shows 3.8-Month Survival Benefit, FDA Guides Phase 3 Path Forward - StockTitan
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA - marketscreener.com
Kazia's Paxalisib Shows Promise in Breast Cancer Trial: Key Data Released at SABCS - StockTitan
Kazia sets FDA meeting for glioblastoma drug pathway - Investing.com India
Kazia Therapeutics Announces Granting of Type C Meeting with FDA to Discuss Potential Next Steps for Paxalisib in the Treatment of Newly Diagnosed Glioblastoma Multiforme - StockTitan
U.S. shares higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.65% - MSN
Upcoming Stock Splits This Week (October 28 to November 1) – Stay Invested - Nasdaq
Kazia Therapeutics Adjusts ADS Ratio to Boost Nasdaq Listing - Yahoo Finance
B2i Digital Acting as Marketing Partner for Maxim Group's 2024 Healthcare Virtual Summit - Benzinga
Paxalisib shows promise in brain metastasis treatment - Investing.com
Market Recap: Kazia Therapeutics Limited ADR (KZIA)’s Positive Momentum, Closing at 0.43 - The Dwinnex
Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring PI3K Pathway Mutations at the American - StockTitan
Kazia Therapeutics Limited ADR (KZIA) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Kazia Therapeutics Limited Adr (KZIA) 財務データ
収益
当期純利益
現金流量
EPS
2.51%
大文字化:
|
ボリューム (24 時間):